Sanofi
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SNW.F | SANOFI.BO | PFE | BIIB | 0QYQ.IL | GLAXO.BO | |
|---|---|---|---|---|---|---|
| Market cap | 100.84B | 77.83B | 175.50B | 37.61B | 218.56B | 424.73B |
| P/E (TTM) | 24.3 | 21.8 | 44.0 | 110.2 | 40.3 | 44.5 |
| Forward P/E | 9.7 | 19.0 | 10.6 | 15.6 | — | 37.0 |
| Price/book | 1.4 | 9.4 | 2.1 | 2.0 | 10.3 | 24.9 |
| Dividend yield | 5.11% | 3.56% | 5.59% | — | 3.81% | 1.75% |
| 1-year change | −5.23% | −28.70% | +21.90% | +62.24% | +38.91% | +6.17% |
| Today | +0.89% | +0.11% | +2.63% | +2.22% | +1.98% | −1.00% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All SNW.F news ›Analysts Conflicted on These Healthcare Names: Sanofi (OtherSNYNF), Arvinas Holding Company (ARVN) and Halozyme (HALO)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sanofi (SNYNF), Arvinas Holding Company (ARVN) and Halozyme (HALO). In a report released today, Sachin Jain from Bank of America Securities…
Sanofi and Regeneron Advance Dupixent Coformulation in Key Phase 1 Study
Regeneron Pharmaceuticals (REGN), Sanofi SA (SNY) announced an update on their ongoing clinical study. The trial evaluates a coformulated Dupixent plus berahyaluronidase alfa injection versus standard Dupixent alone. The goal is to see if…
Sanofi (SAN:CA) Q3 2026 Earnings Call Transcript
Sanofi (SAN:CA) Q3 2026 Earnings Call October 30, 2026 8:30 AM EDT Thomas Larsen - Head of Investor Relations & General MedicinesBelen Garijo Lopez - CEO & DirectorFrançois-Xavier Roger - Executive VP & CFOPaulo Fontoura - EVP, Global Head…
Stocks Flashing Renewed Technical Strength: Sanofi ADR
Sanofi ADR shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82. Investors.com will undergo scheduled maintenance from 10:00 PM ET to 2:00 AM ET and some features may be unavailable. We…
Regeneron expects 2027 R&D expense to rise by a mid-teens percentage while recording a $1B Sanofi upfront payment in Q4
"We're pleased to report another quarter of strong performance, driven by outstanding commercial execution and a large and diverse pipeline that is continuing to deliver on its promise." (CEO Leonard ... Earnings Call Insights: Regeneron…
Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up
A strong third quarter has made Regeneron Pharmaceuticals (NASDAQ:REGN | REGN Price Prediction) a standout healthcare gainer on a day when tech stocks are selling off. In morning trading, Regeneron stock has climbed to $919.58, up 12%.…
Regeneron, Sanofi Surge As Dupixent Wallops Sales Forecasts
BREAKING: Nasdaq Futures Fall Over 2% As Amazon, Intel Fuel AI Rout The company's Sanofi (SNY)-partnered immunology drug, Dupixent, brought in $6.54 billion vs. forecasts for $6.15 billion in sales. Sanofi records global sales of Dupixent…
Sanofi lifts profit outlook on strong Dupixent sales
The French drugmaker reported third-quarter business earnings of €3.55 per share, beating analyst estimates by €2.04. Revenue rose 16.2% year over year to €14.44B, exceeding expectations by €1.12B. Sales from pharmaceutical launches surged…
Sanofi eyeing pipeline deals ahead of Dupixent patent loss
Sanofi's chief executive has said that adding to the group's pipeline through M&A and licensing deals will be "critical" as it prepares for generic competition to top-selling drug Dupixent in the early 2030s. Belén Garijo, who took over…
Sanofi lifts expectations for 2026 sales growth, looks to M&A
LONDON, Oct 30 (Reuters) – French drugmaker Sanofi said on Friday it expects sales to grow by a “low-teens percentage” this year, up from a previous forecast of 10% sales growth, banking on strong demand for its blockbuster asthma drug…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com28
- seekingalpha.com14
- markets.businessinsider.com6
- theglobeandmail.com5
- ir.recursion.com3
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.